Skip to Content

Arnold School of Public Health


Study finds new pathway for treating non-alcoholic fatty liver disease

December 8, 2016 | Erin Bluvas, bluvase@sc.edu 

Researchers* from the University of South Carolina, Duke University, University of Alabama at Birmingham, and Metabolon Inc. Research Triangle Park have discovered a new pathway in the liver that opens the door to treat non-alcoholic fatty liver disease, a condition that affects up to 25 percent of the population and may lead to cirrhosis and eventually liver cancer or failure, and likely other liver diseases. The study was published in Free Radical Biology & Medicine, one of the leading scientific journals in the field of oxidative stress and medicine.

The team found that an ion channel protein (TRPV4), which can rapidly permeate calcium ions into liver cells where calcium functions as a “switch” inside the cells, which in turn leads to release of a gas, nitric oxide. This gas then blocks one of the liver enzymes (CYP2E1) that is a major contributor to non-alcoholic liver disease and its progression. Nitrous oxide, released by activation of TRPV4 in the liver thus acts hepato-protective, (i.e., shielding the liver from harm caused by excessive action of CYP2E1).

Now that TRPV4’s capacity to block the development of non-alcoholic fatty liver disease has been discovered, the next step is to harness its preventive and treatment perspective. According to the authors, a new generation of TRPV4 activating chemicals or other measures such as gene-therapy will have to be developed and implemented via clinical trials to prevent/treat non-alcoholic fatty liver disease, oftentimes associated with diabesity—a metabolic dysfunction.

“There are currently no clinically proven drugs to treat non-alcoholic fatty liver disease,” says Saurabh Chatterjee, an associate professor of environmental health sciences at USC’s Arnold School of Public Health and the director of the Environmental Health and Disease Laboratory where the research was led. “Our goal is to find novel pathways in the liver that will result in a road to a cure, and this novel internal defense mechanism within the liver offers a very promising route.”

In addition to revealing the benefits of activating TRPV4, the researchers also warn against the consequences of inhibiting the TRPV4 ion channel, an approach that can enhance hepatotoxicity (i.e., liver damage caused by chemicals), which can result from acetaminophen or alcohol over-consumption.

“This means that one has to be careful when aiming to inhibit TRPV4 for therapeutic purposes, such as when treating pain, inflammation or itching, or other conditions, in particular when inhibiting TRPV4 by systemic application of TRPV4-blockers,” says Wolfgang Liedtke, a professor of neurology, anesthesiology and neurobiology at Duke University School of Medicine who first described TRPV4 16 years ago. “An attractive avenue to meet this therapeutic dilemma is to use herbal-derived TRPV4-activating compounds that might be more ‘gentle’ or targeted genetic manipulations of liver cells aiming to facilitate TRPV4-signaling in the liver when treating non-alcoholic fatty liver disease. These methods could also be a suitable approach to balance an eventually-needed systemic inhibition of TRPV4 that one aims for in order to treat pain, inflammation, fibrotic diseases or lung edema, in order to avoid additional damage to the liver.”

This groundbreaking research has the potential to have a significant impact for both individuals and public health. “This type of research, which seeks novel pathways for treatment of diseases for which there are currently no therapeutic options is vitally important,” notes collaborator and USC Vice President for Research Prakash Nagarkatti. “It opens doors that lead to the breakthroughs patients rely on to improve outcomes, enhance quality of life and even save lives.”

Non-alcoholic fatty liver disease occurs when there is a buildup of extra fat in the liver (i.e., more that 5-10 percent of the liver’s total weight) coupled with liver inflammation that is not caused by alcohol. Affecting both children and adults, this disease tends to occur in individuals who are obese or overweight, have type II diabetes, high cholesterol and triglycerides. However, some people develop non-alcoholic fatty liver disease without any of these risk factors, possibly suggesting genetic risk factors. Healthy liver function is critical because the liver functions as a metabolic and chemical central laboratory in all vertebrate organisms including humans. For example, it processes food and drink into energy and nutrients, produces bile, blood coagulation factors and other blood proteins while processing and removing many harmful substances from blood.

 

*The study was led by Ratanesh Seth, a postdoctoral fellow at the USC Arnold School of Public Health with collaborative inputs from Suvarthi Das (USC Arnold School of Public Health), Diptadip Dattaroy (USC Arnold School of Public Health), Varun Chandrashekaran (USC Arnold School of Public Health), Firas Alhasson (USC Arnold School of Public Health), Gregory Michelotti (Metabolon Inc. Research Triangle Park), Mitzi Nagarkatti (USC School of Medicine), Prakash Nagarkatti (USC School of Medicine), Anna Mae Diehl (Duke University School of Medicine), Darwin P. Bell (University of Alabama at Birmingham), Wolfgang Liedtke (Duke University School of Medicine), Saurabh Chatterjee (USC Arnold School of Public Health, Principal Investigator).

Funding: This work has been supported by NIH Pathway to Independence Award, R00ES019875 and P01AT003961 to Saurabh Chatterjee, US Department of Defense (W81XWH-13-1-0299) and a Harrington Discovery Institute (Cleveland OH) Scholar-Innovator Award to Wolfgang Liedtke. R01DK053792 to Anna Mae Diehl, P01AT003961, P20GM103641, R01AT006888, R01ES019313, R01MH094755 and VA Merit Award BX001357 to Mitzi Nagarkatti and Prakash S. Nagarkatti.